CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

The fall in CRSP stock ... think CRISPR Therapeutics (NASDAQ: CRSP) could more than double your money in the year ahead. If things don't work out, they can quietly lower their price targets ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%. Meanwhile ...

InvestingPro data indicates significant stock price volatility with a ... of innovation in this space means that CRISPR must continuously advance its technology to maintain its competitive position.

CRISPR Therapeutics stock could more than double from recent prices, according to analysts ... of gene therapies that use CRISPR/Cas9 technology to edit genes. Its first treatment, Casgevy ...